ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Systems biology strategy and experimental validation to uncover the pharmacological mechanism of Xihuang Pill in treating non-small cell lung cancer

Zhuang, Zhenjie; Huang, Dan; Sheng, Zhou Rui; Jiang, Haimei; Ye, Zeng Jie; Yuan, Yi; Qin, Binyu; Zhao, Yan; Pan, Hua-Feng*; Tang, Ying*广州中医药大学; 1; y
PHYTOMEDICINE2023-1DOI: 10.1016/j.phymed.2022.154491
5被引23阅读
引用收藏
分享

摘要

Background: Non-small cell lung cancer (NSCLC) accounts for almost 85% of lung cancer-related deaths worldwide. Xihuang Pill (XHP) is a representative anticancer Chinese patented medicine used to treat NSCLC in China. However, to date, a systematic analysis of XHP's antitumour effects and its impact on the immune microenvironment has not been performed. @@@ Purpose: Based on the systems biology strategy and experimental validation, the present study aimed to investigate the pharmacological mechanisms involved in treating NSCLC with XHP. @@@ Methods: A subcutaneous tumour model was established to evaluate XHP's tumour-inhibitory effect in BALB/c nude mice. RNA sequencing (RNA-seq) and bioinformatics analysis were conducted to identify differentially expressed genes (DEGs) and signalling pathways related to XHP treatment. Network analysis based on network pharmacology and protein-to-protein networks was applied to identify the compounds and genes targeted by XHP. External data from the TCGA-NSCLC cohort were used to verify the clinical significance of XHP-targeted genes in NSCLC. The expression of survival-related candidate genes after XHP treatment was verified via qPCR. The protein expression of calcium voltage-gated channel subunit alpha 1C (CACNA1C) in different NSCLC cell lines was analysed in the Human Protein Atlas database (HPA) and DepMap Portal. Using the Estimation of STromal and Immune cells in MAlignant Tumour tissues using Expression data (ESTIMATE) algorithm and the single-sample gene set enrichment analysis (ssGSEA) algorithm uncovered the role of CACNA1C in the NSCLC tumour micmenvironment (TME). @@@ Results: XHP (2 g/kg/d) significantly inhibited the growth of transplanted A549 tumours. RNA-seq identified a total of 529 DEGs (189 upregulated and 340 downregulated). In addition, 542 GO terms, 41 significant KEGG pathways, 9 upregulated hallmarks pathways, and 18 downregulated hallmark pathways were enriched. These GO terms and signalling pathways were closely related to cell proliferation, immunity, energy metabolism, and the inflammatory response of NSCLC. In addition, XHP's network pharmacology analysis identified 301 compounds and 1,432 target genes. A comprehensive strategic analysis identified CACNA1C as a promising gene by which XHP targets and regulates the TME of NSCLC, benefiting patient survival. CACNA1C expression was positively correlated with both the immune score and stromal score but negatively correlated with the tumour purity score. Additionally, CACNA1C expression was significantly correlated with the infiltration levels of 15 types of immune cells and the expression levels of 6 well-known checkpoint genes. @@@ Conclusions: Our results show that by regulating the pathways associated with cell proliferation and immunity, XHP can suppress cancer cell growth in NSCLC. Additionally, XHP may increase the expression of CACNA1C to suppress immune cell infiltration and regulate the expression of checkpoint-related genes, thereby improving the overall survival of NSCLC patients.

学科与关键词

关键词
Xihuang PillNon-small Cell Lung CancerSystems Biology StrategyCalcium Voltage-Gated Channel SubunitAlpha1 CImmune Microenvironment
相关
加载中…
  • Xanthotoxol suppresses non-small cell lung cancer progression and might improve patients' prognosis
    Lin, Xian; Liu, Jingfeng; Zou, Yujiao; Tao, Cheng; Chen, Jian*PHYTOMEDICINE, 2022, 105: 154364.被引 10
  • Deciphering the Effects and Mechanisms of Yi-Fei-San-Jie-pill on Non-Small Cell Lung Cancer With Integrating Network Target Analysis and Experimental Validation
    Yang, Hongxing; Guo, Qiuyan; Wu, Jianbin; Zhong, Lixia; Sun, Lingling; Liu, Wei; Wang, Jigang*; Lin, Lizhu*Frontiers in Pharmacology, 2022, 13: 851554.被引 2
  • A Mechanism Exploration for the Yi-Fei-San-Jie Formula against Non-Small-Cell Lung Cancer Based on UPLC-MS/MS, Network Pharmacology, and In Silico Verification
    Hu, Leihao; He, Canfeng; Mo, Aier; Zhan, Xingkai; Yang, Caizhi; Guo, Wei; Sun, Lingling; Su, Weiwei*; Lin, Lizhu*Evidence-based Complementary and Alternative Medicine, 2023, 2023: 3436814.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
PHYTOMEDICINE
发表日期
2023-01
卷期
第 108 卷
页码
154491
DOI
10.1016/j.phymed.2022.154491
语言
GERMAN
成果收录
SCIE
资助标注
Key-Area Research and Development Program of Guangdong Province, Modernization of Chinese Medicine in Lingnan [2020B1111100011]; "Double First-Class" and Highlevel University Discipline Collaborative Innovation Team Project of Guangzhou University of Chinese Medicine [2021xk23]

作者

  • Z

    Zhuang, Zhenjie (第一作者)

    guangzhou univ chinese med · 1

  • H

    Huang, Dan

    guangzhou univ chinese med · 1

查看全部 10 位作者收起作者
  • S

    Sheng, Zhou Rui

    guangzhou univ chinese med · 1

  • J

    Jiang, Haimei

    guangzhou univ chinese med

  • Y

    Ye, Zeng Jie

    guangzhou univ chinese med

  • Y

    Yuan, Yi

    guangzhou univ chinese med

  • Q

    Qin, Binyu

    guangzhou univ chinese med

  • Z

    Zhao, Yan

    guangzhou univ chinese med

  • P

    Pan, Hua-Feng (通讯)

    guangzhou univ chinese med

  • T

    Tang, Ying (通讯)

    guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417